Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
NCT ID: NCT00970918
Last Updated: 2010-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2609 participants
INTERVENTIONAL
2009-10-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Measurement of the Carotid Intima Media thickness
one time, radiological procedure on both sides of the neck
Blood sample testing for hs-CRP
one time, blood sample taking
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of the Carotid Intima Media thickness
one time, radiological procedure on both sides of the neck
Blood sample testing for hs-CRP
one time, blood sample taking
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with at least two CVD risk factors but not on lipid-lowering agents
Exclusion Criteria
* Subjects on any lipid-lowering drug treatment within the last 3 months prior study entry.
30 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Yeoman, MD
Role: STUDY_DIRECTOR
Asia Pacific Regional Office, AstraZeneca Singapore Pte Ltd 8 Wilkie Road, #07-01 Wilkie Edge, Singapore 228095
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, Beijing Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Gurgaon, , India
Research Site
Jaipur, , India
Research Site
Meerut, , India
Research Site
Denpasar, Bali, Indonesia
Research Site
Bandung-Jawa, Barat, Indonesia
Research Site
Semarang-Jawa, Tengah, Indonesia
Research Site
Surabaya, Timur, Indonesia
Research Site
Kuching, Sarawak, Malaysia
Research Site
Manila, Manila, Philippines
Research Site
Quezon City, , Philippines
Research Site
Seoul, Seoul, South Korea
Research Site
Kaohsiung, Taipei, Taiwan
Research Site
Shilin, Taipei, Taiwan
Research Site
Taoyuan, Taipei, Taiwan
Research Site
Patumwan, Bangkok, Thailand
Research Site
Hanoi, Hanoi, Vietnam
Research Site
Ho Chi Minh City, Ho Chi Min, Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D3560L00092
Identifier Type: -
Identifier Source: org_study_id